ÂÜÀòÂÒÂ×

Jack Bech Nielsen is a seasoned executive with extensive experience in the biotechnology sector. Currently serving as Managing Partner at Vivo Capital since March 2017, Jack also holds various board positions across several companies, including Ocelot Bio, IO Biotech, Instil Bio, ALX Oncology, Aligos Therapeutics, HARMONY BIOSCIENCES, and previously Reata Pharmaceuticals and MacuLogix. Notable achievements during Jack's tenure include the successful public offerings of several companies on Nasdaq, with significant milestones such as Reata's IPO in 2016 and its acquisition by Biogen in 2023. Jack holds an MSc in Chemistry and Biochemistry and an MMT/MBA in Management of Technology and Economics from the Technical University of Denmark.